388 related articles for article (PubMed ID: 20433654)
1. [Therapy of candidemia and invasive candidiasis according to guidelines].
Glöckner A
Mycoses; 2010 May; 53 Suppl 1():30-5. PubMed ID: 20433654
[TBL] [Abstract][Full Text] [Related]
2. [Echinocandins in invasive candidiasis].
Glöckner A; Cornely OA
Med Klin (Munich); 2008 Jun; 103(6):397-405. PubMed ID: 18548209
[TBL] [Abstract][Full Text] [Related]
3. Treatment of invasive candidiasis with echinocandins.
Glöckner A; Steinbach A; Vehreschild JJ; Cornely OA
Mycoses; 2009 Nov; 52(6):476-86. PubMed ID: 19076282
[TBL] [Abstract][Full Text] [Related]
4. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
6. Candidemia and invasive candidiasis: a review of the literature for the burns surgeon.
Ha JF; Italiano CM; Heath CH; Shih S; Rea S; Wood FM
Burns; 2011 Mar; 37(2):181-95. PubMed ID: 20395056
[TBL] [Abstract][Full Text] [Related]
7. Anidulafungin: a new echinocandin with a novel profile.
Vazquez JA
Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
[TBL] [Abstract][Full Text] [Related]
8. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.
Natarajan G; Lulic-Botica M; Aranda JV
J Perinatol; 2009 Nov; 29(11):738-43. PubMed ID: 19776753
[TBL] [Abstract][Full Text] [Related]
9. Echinocandins: pharmacokinetic and therapeutic issues.
Cleary JD
Curr Med Res Opin; 2009 Jul; 25(7):1741-50. PubMed ID: 19557937
[TBL] [Abstract][Full Text] [Related]
10. Update on echinocandin antifungals.
Kauffman CA; Carver PL
Semin Respir Crit Care Med; 2008 Apr; 29(2):211-9. PubMed ID: 18366002
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
Lichtenstern C; Nguyen TH; Schemmer P; Hoppe-Tichy T; Weigand MA
Mycoses; 2008; 51 Suppl 1():35-46. PubMed ID: 18471160
[TBL] [Abstract][Full Text] [Related]
12. [Micafungin in invasive candidiasis among oncohematological patients].
Jarque I; Angel Sanz M
Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
[TBL] [Abstract][Full Text] [Related]
13. [Potential of anidulafungin in hematological patients].
Vázquez López L; Ruiz Camps I
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():44-50. PubMed ID: 19572434
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis].
Montejo González JC; Catalán González M; León Gil C
Rev Iberoam Micol; 2008 Jun; 25(2):107-18. PubMed ID: 18473505
[TBL] [Abstract][Full Text] [Related]
15. The echinocandins: three useful choices or three too many?
Bal AM
Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
18. Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy.
Garnacho-Montero J; Díaz-Martín A; Cayuela-Dominguez A
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S137-41. PubMed ID: 19013338
[TBL] [Abstract][Full Text] [Related]
19. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials.
Vardakas KZ; Samonis G; Michalopoulos A; Soteriades ES; Falagas ME
Crit Care Med; 2006 Apr; 34(4):1216-24. PubMed ID: 16484923
[TBL] [Abstract][Full Text] [Related]
20. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
